Who are Cord blood's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Casgevy, hUCB, Haplo-cord HCT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cord-blood.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Cord blood — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cord blood (Cord blood) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hematopoietic stem cell therapy. Area: Hematology/Oncology.

marketed Hematopoietic stem cell therapy Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cord blood (Cord blood) — New York Medical College. Cord blood is a source of hematopoietic stem cells and progenitor cells that can differentiate into various blood cell types and immune cells for therapeutic transplantation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cord blood TARGET	Cord blood	New York Medical College	marketed	Hematopoietic stem cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
hUCB	hUCB	StemCyte Taiwan Co., Ltd.	marketed	Allogeneic hematopoietic stem cell therapy
Haplo-cord HCT	Haplo-cord HCT	The First Affiliated Hospital of Soochow University	phase 3	Hematopoietic stem cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hematopoietic stem cell therapy class)

New York Medical College · 1 drug in this class
The First Affiliated Hospital of Soochow University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cord blood — Competitive Intelligence Brief. https://druglandscape.com/ci/cord-blood. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab